MAIA Biotechnology has filed a notice of an exempt offering of securities to raise $5,700,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, MAIA Biotechnology is raising up to $5,700,000.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Vlad Vitoc played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About MAIA Biotechnology
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company’s lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.
To learn more about MAIA Biotechnology, visit http://maiabiotech.com/
Contact:
Vlad Vitoc, President and Chief Executive Officer
312-416-8592
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.